Comparison of machine learning algorithms for predicting cognitive impairment using neuropsychological tests

Chanda Simfukwe1, Seong Soo A An1, Young Chul Youn2

  • 1Department of Bionano Technology, Gachon University, Seongnam-si, South Korea.

PubMed
Summary

Machine learning models, particularly random forest, effectively classify cognitive impairment using neuropsychological tests. These models optimize diagnosis for mild cognitive impairment and Alzheimer's disease dementia, improving accuracy and reducing missed cases.

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
108
Introduction to Cognitive Psychology01:20

Introduction to Cognitive Psychology

Cognitive psychology is the field of psychology dedicated to examining how people think. It attempts to explain how and why we think the way we do by studying the interactions among human thinking, emotion, creativity, language, and problem-solving, as well as other cognitive processes. Cognitive psychology studies how information is processed and manipulated in remembering, thinking, and knowing.
This field emerged in the mid-20th century, following a period dominated by behaviorism, which...
452
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452